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Despite extensive research and numerous publications biomarkers have yet to fulﬁll their promise as prognostic indicators that can
be widely used in the care of patients with heart failure. Speciﬁc clinical applications need to be identiﬁed for informative analyses
of data that emphasize the most directly applicable measures of predictive performance.
1.Introduction
A number of secondary analyses of data gathered during
clinicaltrialsandobservationalcohortstudieshaveidentiﬁed
several biomarkers that have been touted as “powerful
predictors” of morbid events and mortality in patients with
heart failure [1, 2]. The resources that are being devoted to
study molecular pathophysiology and genetics most likely
will lead to identiﬁcation of additional biomarkers that will
provide prognostic information. In an era of evidence-based
medicine when implementation of the results of funded
research is very important, there has been a remarkable
paucity of studies to make available forthright evidence
that supports the clinical use of biomarkers as prognostic
indicators in the care of patients with heart failure. Most
published reports concerning the prognostic information
provided by biomarkers including our own have not gone
beyond merely using regression analyses to report associa-
tions betweenbiomarkersandpatient outcomesandposthoc
discriminationofoutcomesthatarenotdirectlyapplicableto
prospective predictions needed for clinical practice. To sup-
port the clinical use of biomarkers as prognostic variables,
investigators need to propose speciﬁc clinical applications,
report more pertinent statistical analyses such as predictive
values, and study patients typically encountered in clinical
practice.
2. What Is the Use of PrognosticMarkers for
Care of Patients with Heart Failure?
A prognostic indicator (predictor) can be any variable
or combination of variables that is measured to make
probabilistic predictions about whether a deﬁned clinical
outcome will or will not occur. This deﬁnition includes
risk factors that might be used to estimate the risk of
developingheartfailureandprognosticindicatorsthatmight
be used to help determine the prognosis of patients who
have an established diagnosis. Although studies of the use of
biomarkers such as brain natriuretic peptide (BNP) to guide
treatment decisions based on the pathophysiology of heart
failure have addressed a very important potential clinical
use of biomarkers, studies have not focused on the clinical
use of biomarkers as prognostic variables [3, 4]. To conduct
practical studies of biomarkers as prognostic indicators we
need to focus on speciﬁc decisions encountered in practice
or by policymakers that depend, in part, on a prognostic
or risk assessment. Heart failure guidelines do employ
prognostic factors to recommend who should be treated
with medications and devices [5]. For example, recommen-
dations for cardiac resynchronization therapy are based, in
part, on a patient’s ejection fraction, QRS interval, and
NYHA class. However, these recommendations are driven
primarily by the characteristics of the patients that were2 Cardiology Research and Practice
included in clinical trials that demonstrated eﬃcacy rather
than an explicit risk or prognostic assessment. A decision
framework that places patients into diﬀerent prognostic or
risk groups who would be treated diﬀerently is needed to
facilitate clinical studies of biomarkers as useful prognostic
indicators. For example, some have reasonably suggested
that measurement of BNP before discharging patients from
hospital care for heart failure might be useful to identify
those who have a small chance of an early readmission
and would not need more intense follow-up or disease
management [6]. Conversely, health care providers might
want to identify patients with heart failure whose level of risk
of subsequent hospital admission warrants closer medical
monitoring. Bettencourt et al. reported that N-terminal
pro-BNP was associated with hospitalization-free survival
after patients were discharged from a hospital admission for
heartfailure[7].Theypresentedhospitalization-freesurvival
curves for prognostic groups deﬁned by the median N-
terminal pro-BNP. Below the median value in their sample
the event rate was a little over 20% after 6 months. The
important question clinicians need to address is whether
t h i sc u m u l a t i v er a t eo fr e a d m i s s i o no rd e a t hi sl o we n o u g h
to forego closer postdischarge follow-up? How low would
the risk of readmission have to be before most health care
providers would be willing to forego closer follow-up, and
what level of N-terminal pro-BNP can predict the clinically
acceptable level of risk? To date, most studies of prognostic
biomarkers have not been designed or analyzed to address
these types of clinically important questions. One recent
study did suggest how a multivariable prediction model
for mortality could be used to identify patients who most
likely would not beneﬁt from an implantable cardioverter-
deﬁbrillator [8].
In practice, clinicians implicitly classify each individual
patient into a dichotomy of those that have a prognosis
or level of risk that in the practitioner’s judgment either
does or does not warrant use of a medical intervention. The
dichotomyisoftenthoughtaboutinrelativequalitativeterms
such as “high risk” or “higher risk” rather than estimates
of the probability that an outcome will or will not occur
within a speciﬁed period of time. The outcome probability
thresholds that help deﬁne clinical decision dichotomies
need to be made more explicit to design and analyze studies
that seek to determine whether measurement of one or more
biomarkers substantially improves the ability of health care
providers to classify patients into diﬀerent risk or prognostic
groups. We need to elicit a clinical consensus for outcome
probability thresholds for the proposed clinical uses of a
biomarker. Alternatively, investigators could propose and
justify a decision threshold. Most likely these thresholds
will be a bit fuzzy and there may be a range of equivocal
outcome probabilities. Ideally the thresholds should take
into account the net beneﬁt, risk, and costs of interventions
that would or would not be used in diﬀerent prognostic
groups. Nevertheless, pivotal studies of the use of prognostic
biomarkers need to describe the clinical scenario for the
proposed use and the prognostic or risk groups that would
be treated diﬀerently. In other words, what does a patient’s
risk of adverse outcome have to be before a speciﬁc type of
medical care is oﬀered or withheld? If the answer is that any
level of risk generally warrants medical intervention, then
there is no need for biomarkers as prognostic predictors.
For example, angiotensin converting enzyme inhibitors are
generally recommended for patients with a left ventricular
ejection fraction less than 35% irrespective of their absolute
level of risk of adverse clinical outcomes [5].
3. What Is the Most Pertinent Measure
of PredictivePerformance?
Studies of prognostic indicators typically report a variety of
statistical analyses including some newer methods such as
reclassiﬁcation tables [9, 10]. Most of these statistics are not
directly applicable to clinical practice. The clinician’s or pol-
icymaker’s objective is usually to place patients into groups
that would be treated diﬀerently recognizing that there will
be substantial prediction errors for individual patients in
each group [11, 12]. Currently use of prognostic indicators
in the care of heart failure is largely limited to qualitative
characterization of patients enrolled in clinical trials rather
than to making quantitative outcome predictions. However,
prognostic biomarkers could be used to select patients for
clinical trails in a manner that is more explicitly based on
predicted outcome probabilities. Currently, the mortality
rate in many cohorts of study-eligible patients with heart
f a i l u r ei st o ol o wt ob ea b l et od e t e c tas u r v i v a lb e n e ﬁ t
without a prohibitively large and costly study. Whether one
or more prognostic indicators can help identify patients
who have a “high-enough mortality risk” is an important
question [13]. To answer this question, one ﬁrst has to deﬁne
“high risk” according to how patients would be selected for
thetreatmentinpractice.Forthesakeofdiscussion,letussay
we want to treat patients who have at least a 10% estimated
probability of dying within one year.
Typically, clinical trials like the Valsartan Heart Failure
Trial (Val-HeFT) include baseline assessments of several rec-
ognized prognostic indicators such as age, NYHA class, left
ventricular ejection fraction, systolic blood pressure, renal
function (serum creatinine, estimated glomerular ﬁltration
rate, blood urea nitrogen, and presence of proteinuria),
serum sodium and albumin concentrations, hemoglobin,
comorbidities including diabetes and atrial ﬁbrillation, and
current treatments [14]. If we were to use these available
assessments to somehow estimate each patient’s 1-year
mortality risk and select a group whose predicted risk during
the ﬁrst year is at least 10%, the most relevant measure of
our prognostic performance would be whether the observed
1-year mortality in the selected group was indeed at least
10%. This could be determined by estimating the positive
predictive value (PPV), the observed percentage of subjects
placed in the “higher-risk” group who die within one year.
T h en e g a t i v ep r e d i c t i v ev a l u e( N P V ) ,t h ep e r c e n t a g eo f
excluded “lower-risk” subjects who do not die within one
year, might be of interest as well.
After reviewing the extensive literature about the prog-
nostic information provided by the previously listed baseline
variables in the Val-HeFT data base, we were not very
conﬁdent in our ability to select study-eligible patients whoCardiology Research and Practice 3
would have at least a 10% risk of dying within 1 year.
Therefore, baseline variables collected in Val-HeFT were
analyzed to help us select patients based on their predicted
probability of dying within the ﬁrst year of follow-up. We
did not try to optimize the prediction model that is merely
being used as example and only included the subjects who
had data for all variables including the biomarkers that are
discussed herein (n = 3,551 out of the 5,010 in the Val-HeFT
study). Consistent with many previous studies, several of the
baseline variables (age, NYHA class, systolic blood pressure,
ejection fraction, serum sodium, glomerular ﬁltration rate,
proteinuria and hemoglobin) were statistically signiﬁcant in
a multivariable logistic regression model of the probability
of dying within a year. Given the estimated regression
coeﬃcients, we entered each patient’s baseline values for the
predictors into the logistic regression equation to calculate
each subject’s predicted probability of dying within the ﬁrst
year. The PPV in the group that had a predicted probability
of dying of at least 0.1(10%) was 16.6% (200 deaths out of
1206 subjects). Thus, we could use these clinical variables
to select a subset of patients among whom at least 10%
would be expected to die during the ﬁrst year assuming
the prediction model would be valid for future patients as
well. Overall, use of the prediction model would enroll 34%
(1206/3551)ofthesubjectsscreened;however,thoseenrolled
wouldhavehigherexpectedﬁrst-yearmortality(16.6%)than
theentirescreenedgroup(9.3%).Useofthepredictivemodel
would exclude the remaining 66% of screened patients from
enrollment(treatment).TheNPVwas94.4%(2214survivors
outof2345subjectswereclassiﬁedas<10%risk).Thus,5.6%
of the patients who would be excluded from a trial based on
this prediction model would be expected to die.
Clearly the estimated predictive values will change as
follow-up continues and more patients experience the out-
comeevent being predicted or are lost to follow-up. The PPV
inapatientgroupclassiﬁedashaving≥10%mortalityduring
the ﬁrst year can be summarized using time-to-event plots,
for example, plots of the cumulative mortality. The NPV
in the patient groups classiﬁed as having ≤10% mortality
during the ﬁrst year can be summarized using Kaplan-Meier
plots of cumulative survival.
Less clinically relevant to assessing the predictive model’s
performance, the estimated sensitivity of the predictive
model was 60% at the cutoﬀ for predicted probabilities
of ≥0.1 (10%). Thus, if we elected to enroll the 34%
(1206/3551) of study-eligible subjects with ≥10% predicted
probability of dying and looked back a f t e ro n e - y e a re l a p s e d
we would expect to have included 60% of the subjects
who died. The estimated speciﬁcity was 69%. Use of this
predictive model would be expected to exclude 69% who
would not die.
4. HowMuchMightNewerBiomarkersImprove
PredictivePerformance?
Several previous reports suggested that biomarkers including
BNP and serum troponin T measured by a highly sensitive
assay (hs-TnT) are associated with all-cause mortality [10,
15, 16]. The median (interquartile range) for the baseline
BNP levels in the Val-HeFT sample was 109 (45 to 254pg/
mL) and 13.7 (7.3 to 23.4ng/mL) for hs-TnT. What’s the
mostinformativewaytodeterminewhetheradditionofthese
biomarkers to the baseline clinical prediction model would
improve the predictive performance?
4.1. Measures of Association. When the natural logarithmic
transformations of both BNP and hs-TnT levels were added
to the previous baseline clinical prediction model, both were
independently associated with 1-year mortality (odds ratio
for BNP = 1.4 with 95% conﬁdence interval 1.2 to 1.5;
P<. 0001 and hs-TnT = 1.7 with 95% conﬁdence interval
1.4 to 2.0; P<. 0001). However, ﬁnding a statistically
signiﬁcant independent association (in this example a sta-
tistically signiﬁcant odds ratio) between a predictor and an
outcome event is not suﬃc i e n te v i d e n c et oc o n c l u d et h a ta
variable will substantially improve predictive performance
[17]. Researchers often suggest that a biomarker is a “pow-
erful predictor” based on weak associations that are highly
statistically signiﬁcant. Statistical signiﬁcance only indicates
that the observed association was most likely not due to
random sampling variation. Although the odds ratios for
BNP and hs-TnT were highly statistically signiﬁcant in this
example, the magnitude of the increases in relative odds
associated with a logarithmic increase in these biomarkers
suggest that they will not greatly enhance our ability to
discriminate those who did versus did not die within one
yearofthebaselineassessment.Theoddsratioforapredictor
in a multivariable model needs to be much greater 3.0 to
adequately discriminate outcome groups [17]. The odds
ratio for the logarithm of the C-reactive protein level was
only 1.1 (95% conﬁdence interval 0.98 to 1.24; P-value =
.11) when added to the baseline clinical prediction model.
Thus,addingthisbiomarkerisevenlesslikelytosubstantially
improve our predictive performance.
4.2. ROC Curves. Evaluations of prognostic indicators often
report receiver operating characteristic (ROC) curves as
retrospective measures of discrimination of those that did
or did not experience the outcome event during a speciﬁed
period of time. Adding the BNP and hs-TnT to the baseline
model of clinical variables improved the area under the ROC
curve from 0.68 (95% conﬁdence interval 0.65 to 0.71) to
0.73 (95% conﬁdence interval 0.70 to 0.76; P<. 00001) as
shown in the Figure 1 .H o w e v e r ,t h eR O Cc u r v e sc o m p a r e
the sensitivity of the prediction models over all, mostly
irrelevant, values of speciﬁcity. If one is interested in com-
paring sensitivities and speciﬁcities of prediction models,
the comparison should focus on the threshold of predicted
probability that will be used to deﬁne the prognostic groups
that will be treated diﬀerently. In our example, the cut
point for predicted probability of interest is 0.1 (a 10%
probability of dying within 1 year) corresponding to the
points marked by circles on ROC curves in the Figure 1.
The estimated sensitivity of the prediction model with the
additional biomarkers was 65.6% (versus 60.4% without the
biomarkers) and the speciﬁcity was 69.4% (versus 68.8%
without the biomarkers). However, estimates of sensitivities
and speciﬁcities are not suﬃcient to determine whether or4 Cardiology Research and Practice
Table 1: Reclassiﬁcation of Subjects into Prognostic Groups by Adding Two Biomarkers, BNP and hs-TnT, to a Prediction Model Based on
Other Baseline Assessments.
Model 1: Baseline Assessments Model 2: Baseline Assessments+ Biomarkers
Predicted Probability <10% Predicted Probability ≥10% Total
Predicted Probability <10%
Number of subjects 2003 (85%)
∗ 342 (15%) 2345
Observed Dead 4.4% 12.3% 5.6%
P r e d i c t e dD e a dM o d e l1 5 . 7 % 7 . 8 % 6.0%
Predicted Probability ≥10%
Number of subjects 345 (29%) 861(71%) 1206
Observed Dead 7.2% 20.3% 16.6%
Predicted Dead Model 1 13.0% 16.9% 15.8%
Total
Number of subjects 2348 (66%) 1203 (34%) 3551
Observed Dead 4.9% 18.0%9 . 3 %
P r e d i c t e dD e a dM o d e l2 5.0% 17.8%
∗Percentages in parentheses are calculated across each row.
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Figure 1: ROC curves. Sensitivity versus 1 minus speciﬁcity for
discriminating subjects who did or did not die within 1 year based
on all possible cut points of predicted probabilities derived from a
prediction model that included several baseline clinical assessments
(Clinical model) and the same model plus two biomarkers, BNP
and hs-TnT. The circles on each curve correspond to the cut point
of interest in this example, that is those with a ≥10% predicted
probability of dying within 1 year.
not adding the biomarkers improved our ability to select a
group of subjects whose mortality would be predicted to be
at least 10%. The PPV in the group of subjects that had an
estimated probability of dying of at least 0.1(10%) was 18%
after the addition of the biomarkers (versus 16.6% before)
and the NPV was 95.1% (versus 94.4% before). The more
clinically useful predictive values cannot be gleaned from
ROC curves. The improvement in the PPV suggests that
subjects selected with the aid of the additional biomarkers
would be more likely to die within a year which could be
considered an improvement for the purpose of selecting
higher risk subjects. However, the increase in the PPV was
not substantial or statistically signiﬁcant (the relative PPV is
1.09 with a 95% conﬁdence interval of 0.9 to 1.3; P = .35)
[18]. Even if the relative PPV was statistically signiﬁcantly
greater than one, further evaluation would be necessary
to decide whether small improvement in predictive value
justiﬁes the additional costs of measuring these biomarkers
[19].
4.3.ReclassiﬁcationTables. Reclassiﬁcationtablesareincreas-
ingly used by investigators to help compare diﬀerent meth-
ods of risk assessment [20, 21]. A reclassiﬁcation table for
the Val-HeFT example is presented in the Table 1 .T h e
addition of BNP and hs-TnT reclassiﬁed 342 (15%) of the
2345 subjects who were classiﬁed using the other baseline
clinical variables as having a predicted probability of dying
within 1 year as <10%. Furthermore, 345 (29%) of the 1206
subjects who were previously classiﬁed as having a predicted
probability of dying within 1 year as ≥10% were reclassi-
ﬁed. Judging by the smaller diﬀerences between observed
and predicted mortality percentages for the column totals
compared to the row totals of the Table 1, the model with the
two additional predictors appears to be better calibrated to
the observed outcomes, that is, the predictive values for each
prognostic group. In the prognostic groups with a predicted
probability of dying under 10% the observed and predicted
mortality percentages were 5.6% and 6.0%, respectively, in
thebaselinemodel,comparedto4.9%and5.0%withthetwo
additional biomarker predictors. In the prognostic groups
with a predicted probability of dying ≥10% the observed
and predicted mortality percentages were 16.6% and 15.8%
in the baseline model, compared to 18.0% and 17.8%
with the two additional biomarker predictors. Investigators
can report a statistical test to compare the observed andCardiology Research and Practice 5
predicted mortality for each model [22]. For the baseline
clinical model the J2 statistic is 1.02 and the associated P-
value is .31. For the baseline clinical model plus BNP and
hs-TnT the J2 statistic is 0.12 and the associated P-value
is .73. Thus, the observed and predicted mortalities in the
deﬁned prognostic groups were not statistically signiﬁcantly
diﬀerent for either prediction model. The two J2 statistics
do not indicate whether or not the small improvement in
model calibration associated with the addition of the two
biomarkers was statistically signiﬁcant (not likely due to
sampling variation) or clinically signiﬁcant.
Note the observed percentages dead in the row and
column totals for the prognostic groups where the predicted
probability was ≥10% are the PPV’s cited earlier, 16.6%
for model 1 and 18% for model 2. The percentages of
observed dead in the row and column totals where the
predicted probability was <10% are the complement of the
NPV’s cited earlier, 100% − 94.4% = 5.6% for model 1
and 100% − 95.1% = 4.9% for model 2. In this example,
both prediction models classiﬁed about the same number
(percentage) of subjects into each prognostic group, but they
were not entirely the same subjects. Thus, the reclassiﬁcation
tables provide some interesting insights into the eﬀects of
adding the biomarkers on the reclassiﬁcation of subjects and
the calibration of group predictions to the predictive values.
Reclassiﬁcation tables can also be retrospectively com-
piled separately for those who did or did not die within
the speciﬁed time period to estimate the net reclassi-
ﬁcation improvement (NRI) [23]. Among the deceased,
reclassiﬁcations out of the prognostic group with predicted
probabilities of dying under 10% would be an improvement
whereas reclassiﬁcations in the opposite direction would be
undesirable. In the example, the classiﬁcation of 42 out of
331 deceased (12.7%) was better and the classiﬁcation of 25
deceased subjects (7.6%) was worse when BNP and hs-TnT
wereaddedtothepredictionmodel.Thenetimprovementin
classiﬁcationof deceasedsubjects was 12.7%−7.6% or 5.1%.
Among the survivors, reclassiﬁcations out of the prognostic
group with predicted probabilities of dying ≥10% would
be an improvement whereas reclassiﬁcations in the opposite
direction would represent worse predictive performance. In
the example, the classiﬁcation of 320 out of 3220 survivors
(9.9%) was better and the classiﬁcation of 300 survivors
(9.3%) was worse with the addition of BNP and hs-TnT. The
net improvement in classiﬁcation of survivors was 9.6% −
9.3% or 0.6%. The NRI is the sum of these two net improve-
ments, that is, 5.1% plus 0.6% equal to 5.7%. Statistical tests
are available (not reported herein) to determine whether
any of these three estimates of improvement in classifying
patients into meaningful prognostic groups are signiﬁcantly
diﬀerent from zero. However, in the case of a dichotomous
classiﬁcation of predicted outcome probabilities the net
improvements in each outcome group are equivalent within
rounding error to the previously calculated increases in
sensitivity (65.6%−60.4% = 5.2%) and speciﬁcity (69.4%−
68.8% = 0.6%). Thus, estimating and testing the NRI would
not greatly enhance the evaluation of how much adding
the biomarkers to the baseline clinical prediction model
improved predictive performance.
5. Summary
The research community needs to work in collaboration
with clinicians and policymakers to provide more deﬁnitive
evidence that biomarkers can serve as useful prognostic
indicators. To advance this ﬁeld of study beyond mere
identiﬁcation of biomarkers that provide some prognostic
information, clinical investigators will need to
(i) identify decisions that rely on outcome predictions
such as heart replacement, use of costly devices,
referral to hospice,
(ii) classify outcome probabilities to deﬁne prognostic
or risk groups that would generally be treated
diﬀerently,
(iii) conduct prospective clinical studies of patients
encountered in daily practice to estimate and com-
pare predictive values for patients that are placed in
prognostic groups that would be treated diﬀerently.
Hopefully, studies will be forthcoming to advance this
promising use of biomarkers. However, we should not be
overly optimistic that biomarkers will substantially improve
predictive values [24]. Furthermore, we will have to demon-
strate that measuring biomarkers to place patients in diﬀer-
ent prognostic or risk groups results in a net improvement in
patient outcomes that justiﬁes the additional costs.
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